Variant · Insertion
EGFR P772_H773insH
CI-VAR-00003397Explore in graph →CIViC 2217
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24353160
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| EGFR P772_H773insH | Erlotinib | Predictive | D | Does Not Support Resistance | 2 | submitted | EID5950In transduced cos7 cells, P772_H773insH cells showed increased sensitivity to erlotinib in comparison to cells with T790M resistance mutation, but decreased erlotinib sensitivity in comparison to L858… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available